维普中文期刊产品整合服务

The efficacy and safety of modified FOLFIRINOX as first-line chemotherapy for Chinese patients with metastatic pancreatic cancer

查看全文 作　　者：Zhi-Qiang [1]Wang;Fei [1]Zhang;Ting [2]Deng;Le [2]Zhang;Fen [3]Feng;Feng-Hua [1]Wang;Wei [3]Wang;De-Shen [1]Wang;Hui-Yan [1]Luo;Rui-Hua [1]Xu;Yi [2]Ba;Yu-Hong [1]Li 高影响力作者 机构地区：[1]Department of Medical Oncology,State Key Laboratory of Oncology in South China,Collaborative Innovation Center for Cancer Medicine,Sun Yat-sen University Cancer Center,651 Dongfeng East Road,Guangzhou 510060,Guangdong,People’s Republic of China;[2]Department of Gastrointestinal Medical Oncology,National Clinical Research Center of Cancer,Key Laboratory of Cancer Prevention and Therapy,Tianjin Medical University Cancer Institute and Hospital,Tianjin 300060,People’s Republic of China;[3]Cancer Center,The First People’s Hospital of Foshan,Foshan 528000,Guangdong,People’s Republic of China高影响力机构 出　　处：《Cancer Communications》索引2019年第39卷第1期,共8页高影响力期刊 摘　　要：Background: Oxaliplatin, irinotecan, 5-fluorouracil, and l-leucovorin (FOLFIRINOX) has become one of the first-line treatment options for advanced pancreatic cancer (PC). However, the relatively high rate of grade 3 or 4 adverse events associated with the standard dosage of FOLFIRINOX limits its widespread use in clinical practice. In this study, we were to evaluate the efficacy and safety of a modified FOLFIRINOX regimen as a first-line chemotherapy for Chinese patients with metastatic PC. Methods: Patients with histologically confirmed primary metastatic pancreatic adenocarcinoma with an Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2 were recruited to receive the modified FOLFIRINOX regimen (intravenous infusion of oxaliplatin, 65 mg/m2;irinotecan, 150 mg/m2;l-leucovorin, 200 mg/ m2;and 5-fluorouracil, 2400 mg/m2, repeated every 2 weeks). The treatment was continued for 12 cycles unless the patient had progressive disease (PD), stable disease (SD) with symptom deterioration, unacceptable adverse events, or requested to terminate the treatment prematurely. The primary endpoint was objective response rate (ORR). Results: Sixty-five patients were enrolled from July 2012 to April 2017 in three institutions, and they all received at least one cycle of chemotherapy, with a median of 8 cycles (range 1-12 cycles). No complete response was observed. Twenty-one (32.3%) patients had partial responses, and 27 (41.5%) had SD. The ORR and disease control rate of the study cohort was 32.3% and 73.8%. The estimated median overall survival and progression-free survival were 11.60 (95% confidence interval [CI] 8.76-14.44) and 5.77 (95% CI 5.00-6.54) months. Major grade 3 or 4 adverse events included neutropenia (12.3%) and diarrhea (6.2%). No treatment-related death was observed. Conclusions: Modified FOLFIRINOX was well-tolerated and might be a promising option as first-line therapy for Chinese patients with metastatic PC. 关 键 词：Pancreatic cancer METASTATIC CHEMOTHERAPY FOLFIRINOX Dose modification FIRST-LINE MULTICENTER Overall response rate Efficacy Safety
相关文献

参考文献(15)

引证文献(4)

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1　渝公网安备 50019002500403号　违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费